Tests precision radiation for melanoma that grows despite immune treatment
Tests precision radiation in adults with melanoma that keeps growing during immune therapy.
Plain-language title generated from the registry record
Registry title: Precision Radiation of Immune Checkpoint Therapy Resistant Melanoma Metastases
Key facts
- Where
- Stockholm, SwedenSee the site
Where in Sweden
- Division of Head-Neck, Lung and Skin cancers, Theme Cancer, Karolinska University HospitalStockholm, SwedenTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Karolinska University Hospital
- Trial code
- NCT04793737
- Record updated
- 5 March 2025
- Original description
To evaluate tumor response, survival and adverse effects after precision radiotherapy (SBRT) in melanoma patients with ongoing PD-1 inhibitor treatment that have tumor progression.Read full original descriptionShow less
Precision Radiation of Immune Checkpoint Therapy Resistant Melanoma Metastases
To evaluate tumor response, survival and adverse effects after precision radiotherapy (SBRT) in melanoma patients with ongoing PD-1 inhibitor treatment that have tumor progression.
Inclusion: Age 18 and above; ECOG performance status of 0-1; Signed and dated written informed consent before the start of specific protocol procedures; Patient has initiated PD-1 inhibitor treatment (alone or in combination with CTLA-4 inhibitor) as the first line of therapy for unresectable metastatic cutaneous melanoma and been on the treatment for at least 3 months and progressed on the treatment. Patients with primary or secondary resistance to the PD-1 inhibitor treatment will be included. Progression is defined as at least 30% enlargement of at least one metastasis or appearance of new metastasis. A fine-needle aspiration (FNA) biopsy from a progressing lesion or a new lesion is recommended to confirm the presence of viable tumor cells; Patients on adjuvant treatment with PD-1 inhibitors that during the treatment develop unresectable biopsy confirmed metastases can also be included in the study; Have at least one new or progressing lesion safely amenable to irradiation in the opinion of the treating radiation oncologist AND at least one, not-to-be-irradiated new or progressing lesion measurable by CT or MRI per RECIST 1.1 criteria where up to four radiation target fields are allowed; No contraindication for continuing immunotherapy after the radiotherapy intervention.
Exclusion: A condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 30 days before start of study treatment. Inhaled or topical steroids and adrenal replacement doses >10 mg daily prednisone equivalents are permitted; Concomitant therapy with any anti-tumor medications, other than PD-1/CTLA-4 inhibitors or 30 days before and after treatment in this trial; Prior radiotherapy preventing the study intervention with precision radiotherapy; Location, size or number of metastases is deemed as excessive or not appropriate for precision radiotherapy; Central nervous system (CNS) metastases at baseline, with the exception of those subjects who have previously-treated CNS metastases (surgery ± radiotherapy, radiosurgery, or gamma knife) and who meet both of the following criteria: a) are asymptomatic and b) have no requirement for steroids or anticonvulsants; Has an active infection requiring systemic therapy; Prior malignancy. Subjects who have had another malignancy should be disease-free for 5 years, or should have a history of completely resected non-melanomatous skin carcinoma or successfully treated in situ carcinoma; Inability to understand given information or undergo study procedures according to protocol; Pregnant or breast-feeding. Patients must agree to use safe contraception during and for 3 months after study treatment.